Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Sangamo Therapeutics Inc (SGMO) Com Stk USD0.01

Sell:$9.48 Buy:$9.49 Change: $0.20 (2.16%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$9.48
Buy:$9.49
Change: $0.20 (2.16%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$9.48
Buy:$9.49
Change: $0.20 (2.16%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

Contact details

Address:
7000 MARINA BLVD
BRISBANE
94005
United States
Telephone:
+1 (510) 9706000
Website:
https://www.sangamo.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SGMO
ISIN:
US8006771062
Market cap:
$1.39 billion
Shares in issue:
145.34 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Alexander Macrae
    President, Chief Executive Officer, Director
  • Prathyusha Duraibabu
    Chief Financial Officer, Senior Vice President
  • D. Mark McClung
    Executive Vice President, Chief Business Officer
  • R. Andrew Ramelmeier
    Executive Vice President - Technical Operations
  • Jason Fontenot
    Senior Vice President, Chief Scientific Officer
  • Robert Schott
    Senior Vice President, Head of Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.